Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Neovacs S.A.. (8/30/16). "Press Release: Neovacs to Present at Two Major Investor Conferences. The 18th Annual Rodman & Renshaw Global Investment Conference & Bio Europe 2016". Paris & Boston, MA.

Region Region Köln (Cologne)
  Country Germany
Organisations Organisation Neovacs S.A. (Euronext Growth Paris: ALNEV)
  Group Neovacs (Group)
  Organisation 2 Rodman & Renshaw Conferences LLC
Products Product Rodman & Renshaw Annual Global Investment Conference 2016 New York
  Product 2 BIO-Europe 2016 Köln (Cologne)
Index terms Index term Neovacs–Rodman & Renshaw: investor conference, 201609 supply service Neovacs presents at Rodman & Renshaw Global Investment Conference in NY
  Index term 2 Neovacs–Informa: partnering conference, 201611 supply service Neovacs presents at BIO-Europe 2016 in Cologne
Persons Person Sieler, Miguel (Neovacs 201310 CEO before Bayer France CEO at Bayer since 1975)
  Person 2 Gabriel, Raimund (MC Services 1999–201101– Founder + CEO)

Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced CEO Miguel Sieler will present at the 18th Annual Rodman & Renshaw Global Investment Conference and Bio Europe 2016.

The Rodman & Renshaw Global Investment Conference, being held September 11-13 in New York, NY, will host over 265 public and private companies, and several thousand attendees. The conference will bring together a vast audience of financial and strategic investors with growth companies in the fields of healthcare, natural resources, technology, media and telecommunications, and cleantech. In addition to corporate presentations, the conference facilitates one-on-one meetings with members of the investment community.

Miguel Sieler, CEO of Neovacs, will present the company at Rodman & Renshaw on Monday September 12, from 10:50 to 11:15 am ET at the New York Palace Hotel, on the fourth floor in the Louis Room.

Neovacs will also present at Bio Europe, which will take place November 7-9 in Cologne, Germany. This conference is one of the world’s most important meeting for the biotech Industry. This year Bio Europe event will draw over 3,500 attendees from 60 countries, representing 1,800 companies. It will provide Neovacs with the opportunity to meet with a vast audience of financial and strategic investors, as well as potential high-level partners.

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.


NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14

Investor Relations / Financial Communication Germany – MC Services
Raimund Gabriel

Press / U.S. Inquiries – The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013 /

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Neovacs (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top